fbpx

Singulair Asthma and Allergy Medication Linked to Severe Mental Health Side Effects

The Food and Drug Administration (FDA) has added a stronger box warning to Singulair and its generic montelukast, a popular asthma and allergy medication, after “continued reports of neuropsychiatric events.” Potential side effects include suicidal thoughts and behaviors, agitation, aggression, attention problems, night terrors, depression, confusion, anxiety, hallucinations, memory problems, obsessive-compulsive symptoms, trouble sleeping or restlessness, and uncontrolled muscle movement or shakiness.

Stories of Singulair’s Severe Side Effects

Toni Dye, a mom from Zephyrhills, Florida, says that her daughter Kayla began taking Singulair at the age of 7. Soon after, she started having anxiety, panic attacks, and anger issues as well as nightmares. “She’d wake up in the middle of the night and be running around the house and just screaming,” Dye said. The change was so drastic that Dye and her husband took Kayla off Singulair after only a few weeks. 

That was 10 years ago. Now, at age 17, Kayla still suffers from anxiety, depression, and panic attacks. “I say that we lost our child because she’s not the same child anymore,” Dye added. “It hurts really bad. I feel guilty for not really looking into the drug.”

Angela Mitchell had a similar experience with her son, who started taking Singulair at 18 months old for severe allergies. After about eight months, she learned of the potential side effects and took him off. “He had become so despondent, so disconnected,” she shared. Additionally, he started exhibiting aggressive behaviors, including wanting to self-harm and harm others. 

Jennifer Brown personally experienced the side effects after only six days of taking montelukast for her asthma. “By the fourth day, I was already picturing myself dying,” she said. 

Recent Response From the FDA

All three women said that no one warned them about the risks for severe mental health side effects. In fact, they belong to a Facebook support group of more than 11,000 people with similar stories, many of which are even more severe and involve suicide. 

Members of this group have long pushed the FDA to take action. In March, the organization announced the requirement of the new box warning. “We are taking this action after a review of available information led us to reevaluate the benefits and risks of montelukast use,” the FDA said in its Drug Safety Communication. “Montelukast prescribing information already includes warnings about mental health side effects, including suicidal thoughts or actions. However, many health care professionals and patients/caregivers are not aware of the risk. We decided a stronger warning is needed after conducting an extensive review of available information and convening a panel of outside experts.” 

A black box warning is the strongest warning that FDA can give to a medication. It is meant to increase awareness, especially for prescribing physicians and pharmacists. This label is the first step towards better education about the harmful side effects of Singulair and montelukast. 

For more information about Singulair and its generic version montelukast, contact us today.

Drug Law Journal Legal Sponsorship

Drug Law Journal's publishing and research are sponsored by the DDP Injury Law Group in Washington, D.C. Their legal team is focused on protecting the rights of injury victims.
Furthermore, they understand and appreciate the importance of a trusted attorney-client relationship.
The DDP Injury Law Group uses their years of experience with litigation to ensure their clients can fight for the compensation they deserve.

Always seek the advice of a medical professional when making personal health choices.

The Offices of DrugLawJournal.com are located at:

1800 North Orange Avenue, Suite C
Orlando, Florida 32804

DrugLawJournal.com is sponsored by the DDP Injury Law Group, and therefore may be considered attorney advertising. The information contained on DrugLawJournal.com is provided for informational purposes only, and should not be construed as legal or medical advice on any subject matter. No viewers of this site should discontinue taking a prescribed medication on the basis of any information on this site and should always first consult with a doctor concerning any medication. Viewers should understand that if they refrain from taking prescribed medication without appropriate medical advice they can suffer injury or death.

No viewers of content from this site, clients or otherwise, should act or refrain from acting on the basis of any content included in the site without seeking the appropriate legal or other professional advice on the particular facts and circumstances at issue from an attorney licensed in the viewer’s state. Viewing information from DrugLawJournal.com does not create an attorney-client relationship between you and DDP Injury Law Group or DrugLawJournal.com nor is it intended to do so.The content of DrugLawJournal.com may not reflect current legal developments, verdicts or settlements. Prior results do not predict a similar outcome. For more information, please visit our web site’s disclaimer.

©2024 DrugLawJournal.com | Privacy Policy | Terms & Conditions

Stay Informed

Sign up to receive peroidic updates from our expert team of researchers, highlighting defective drugs, devices, and legal issues related to your health.

Email Catcher
Free Drug and Medical Device Case Review

Free Drug and Medical Device Case Review

Share your story with us and we will reach out to you about your case.

First
Last
Described what happened to you, we will review and reach out to you about your situation.

It is important for those who have suffered injury from dangerous drugs and medical devices to know that they have may have options.

Consumers have the ability to seek legal remedies for their injuries resulting from the negligence of drug and device manufacturers. The first step toward justice and recovery is sharing your story with effective legal counsel. An attorney will help you to better understand the issues and discuss the possibility of compensation for your suffering.

Once you complete the information request above, Drug Law Journal will send the information to a specialist at our legal sponsor’s firm, the DDP Injury Law Group, in Washington, D.C. That specialist will follow-up with you directly to gather further specific information about your case and make an evaluation. If the firm is able to move forward on your case, they will also discuss next steps. Remember – the entire consult and evaluation is free to you. You only need to take the first step to fill out the contact form or call: (800) 597-1870 for immediate assistance.